Moderna and Merck announce advances in cancer vaccine research. Moderna shifted focus toward cancer treatments, sending its stock up 177%. The company developed a tailored mRNA injection designed to fight skin cancer, though its effectiveness has yet to be fully proven. Merck developed a cancer vaccine that could pave the way for a wave of related medical developments.
Opinions on the progress vary. A number of observers attribute success to private sector competition, while others view it as an overdue advance. Additional testing is needed to properly assess the implications of these findings. Still, the results signal a promising direction in cancer treatment.